Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





MORPHOLINE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 110-91-8; **Chemical Formula:** C4H9NO
OSHA had a limit of 20 ppm, with a skin notation, for morpholine. The ACGIH has a 20-ppm TWA limit and a TLV-STEL of 30 ppm, as well as a skin notation. The proposal retained the 8-hour TWA PEL of 20 ppm and added a STEL of 30 ppm; NIOSH concurs that these limits are appropriate (Ex. 8-47, Table N1), and they are established in the final rule. The skin notation is retained. Morpholine is a colorless liquid with an amine-like odor.
Exposure to morpholine produces nasal and bronchial irritation and liver and kidney impairment in animals (Shea 1939/Ex. 1-758); the substance readily penetrates the skin and is highly irritating to the eyes (Jefferson Chemical Company, Inc. 1961, as cited in ACGIH 1986/Ex. 1-3, p. 417). The single oral LD(50) in rats is 1.05 g/kg (range: 0.95 to 1.16 g/kg), and the single skin LD(50) for 24-hour contact is 0.5 ml/kg (Smyth, Carpenter, Weil, and Pozzani 1954/Ex. 1-440). Neither a one-hour exposure to concentrated vapor nor an 8-hour exposure to 8000 ppm was fatal in rats (Smyth, Carpenter, Weil, and Pozzani 1954/Ex. 1-440). Rats were exposed for eight hours daily to a concentration of 18,000 ppm for a total of five days; after the first day, all animals showed severely reddened thoracic walls, and one fatality (from kidney and liver congestion) occurred. A similar fatality occurred on the third day; on day 4, a third rat died, and postmortem examination revealed degeneration of the epithelial lining of the kidney tubules. Three additional deaths occurred after the exposures had ended; autopsy revealed thickened alveoli, emphysema, and liver and kidney effects (Shea 1939/Ex. 1-758).
Reporting on his own reactions to morpholine exposure at a concentration of 12,000 ppm, Shea (1939/Ex. 1-758) complained of nose irritation (after 1 minute) and coughing (after 90 seconds); in addition, when he transferred morpholine by pipette, he experienced sore throat and mucosal irritation. All symptoms disappeared after the experiment stopped (Shea 1939/Ex. 1-758). Skin contact poses a moderately high degree of hazard, which diminishes as the product is diluted with water to less than 25 percent (Jefferson Chemical Company, Inc. 1961, as cited in ACGIH 1986/Ex. 1-3, p. 417). Respiratory irritation but no chronic effects have been reported as a result of industrial exposure (Patty 1963e/Ex. 1-858). In comparison with ammonia, morpholine has a greater potential for systemic toxicity (ACGIH 1986/Ex. 1-3, p. 417).
OSHA received a comment on morpholine from Lawrence Hecker of Abbott Laboratories (Ex. 3-678). Dr. Hecker states (Ex. 3-678, p. 8) that the STEL proposed for morpholine should not be included in the final rule because the health evidence for this substance does not warrant a STEL. OSHA does not agree with Dr. Hecker; there is evidence in the record that morpholine’s effects are experienced even at elevated exposures lasting only one minute (Shea 1939/Ex. 1-758). Because morpholine has a greater potential for systemic effects than does ammonia, a STEL is needed to ensure that short-term excursions substantially above the 8-hour TWA PEL do not occur.
In the final rule, OSHA is retaining the 8-hour TWA limit for morpholine of 20 ppm TWA and the skin notation, and is adding a 15-minute STEL of 30 ppm. The Agency concludes that these limits will work together to protect workers against the significant risk of eye and respiratory tract irritation, which are material impairments of health that are associated with exposures at levels above the 8-hour TWA limit. OSHA is retaining the skin notation for morpholine because of this substance’s ability to be absorbed through the skin in toxic amounts.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue